20/20 Biolabs, Inc.
Key Metrics
Market Snapshot
About
20/20 Biolabs, Inc. (AIDX) is a medical device company based in Gaithersburg, Maryland, known for developing artificial intelligence (AI)-enhanced blood tests aimed at the early detection of diseases.
The company's primary products are laboratory-based blood tests that utilize AI algorithms to analyze biomarkers. Its OneTest for Cancer is designed as a multi-cancer early detection tool, screening for multiple cancer types from a single blood sample. It also offers OneTest for Longevity, which focuses on measuring inflammatory biomarkers associated with chronic conditions and overall health. These tests are intended to be used as part of preventive health screening protocols.
In addition to its diagnostic products, 20/20 Biolabs operates the Clinical Lab Innovation Axcelerator, or CLIAx. This is a CLIA-certified laboratory facility that provides services to other diagnostics start-ups, particularly those based outside the United States, enabling them to conduct clinical testing and development work. Founded in 2000 and originally named 20/20 GeneSystems, Inc., the company rebranded to its current name in March 2025 as part of its focus on broader laboratory-based health solutions. Its business model centers on the sale of its proprietary tests and providing laboratory services to other companies in the diagnostics sector.